drugset / Trial / NCT06310824
Single Dose, Three-arm Study to Compare the Pharmacokinetic Similarity of MAB-22 Versus Prolia®
RandomizedParallel-groupDouble-blindOther
Summary
A Randomized, Double-blind, Controlled, Parallel-group, Single Dose, Three-arm Study to Compare the Pharmacokinetic Similarity of MAB-22 Versus Prolia®
Timeline
- Start
- 2024-06-05
- Primary completion
- 2025-07-22
- Completion
- 2025-07-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Denosumab | Monoclonal antibody | 60 mg | Subcutaneous |
| Subject | MAB-22 | Unknown | 60 mg | Subcutaneous |
Indications
No indication recorded.